

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 37/00, 37/04, C07K 15/28 C07K 15/14		A1	(11) International Publication Number: WO 93/23062 (43) International Publication Date: 25 November 1993 (25.11.93)		
(21) International Application Number: PCT/US93/04136 (22) International Filing Date: 7 May 1993 (07.05.93)		(74) Agents: SAXE, Bernhard, D. et al.; Foley & Lardner, 3000 K Street, N.W., Suite 500, P.O. Box 25696, Washington, DC 20007-8696 (US).			
(30) Priority data: 07/882,177 11 May 1992 (11.05.92) US		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).			
(71) Applicant: IMMUNOMEDICS, INC. [US/US]; 300 American Road, Morris Plains, NJ 07950 (US).		Published <i>With international search report.</i>			
(72) Inventors: HANSEN, Hans, J. ; 2617 North Burgee Drive, Mystic Island, NJ 08087 (US). GRIFFITHS, Gary, L. ; 25 Atmo. Avenue, Morristown, NJ 07960 (US). LEN-TINE-JONES, Anastasia ; R.R. #3 Box 354, Pittstown, NJ 08867 (US). GOLDENBERG, David, M. ; 397 Long Hill Drive, Short Hills, NJ 07078 (US).					
(54) Title: THERAPEUTIC CONJUGATES OF TOXINS AND DRUGS					
(57) Abstract A conjugate useful in cancer or infectious disease therapy is a drug or modified toxin which is a native toxin devoid of a functioning receptor binding domain and a protein which reacts with a substance associated with a targeted cell or pathogen. The targeted substance internalizes the conjugate into the cell cytoplasm, and then kills the cell. The protein prior to conjugation has at least one mercapto group which becomes a site for conjugation to the toxin or drug. Also provided are methods for producing the conjugate, pharmaceutical compositions of the conjugate and uses of the conjugate to prepare medicaments useful in therapy.					

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MC	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam

THERAPEUTIC CONJUGATES OF TOXINS AND DRUGS

BACKGROUND OF THE INVENTION

1- Field of the Invention

The present invention relates to therapeutic conjugates of a drug or modified toxin and a protein which reacts with a substance associated with a targeted cell which internalizes the conjugate into the cell.

The present invention also relates to improved and optimized methods for site-specific conjugation of antibody-10 or antibody fragments with toxins or drugs.

The present invention further relates to compositions and methods useful in cancer therapy.

The present invention further relates to compositions and methods useful in viral, microbial and parasitic therapy.

15 2- Description of the Prior Art

Drugs and toxins which are internalized into a cell are extremely potent cytotoxic agents of cells that are responsible for many human diseases. Because of their high activity, these agents have been attached to monoclonal 20 antibodies in order to form cytotoxic agents which specifically bind to target cells. These immunotoxins are, therefore, very useful in therapy for cancer, viruses, parasites, and other infectious organisms.

Various methods have been used to attach toxins and 25 drugs to monoclonal antibodies; however, a need continues to exist for a site-specific method to form a stable conjugate of a protein, particularly, an antibody or antibody fragment, and a toxin or drug having a therapeutic effect similar to that of a toxin.

30 OBJECTS OF THE INVENTION

One object of the present invention is to readily produce a highly immunoreactive conjugate of a toxin or drug and antibody or antibody fragment which is stable.

Another object of the invention is to provide a method 35 for introducing toxins or drugs into an antibody or antibody fragment.

Another object of the present invention is to provide

medicaments for use in methods of therapy with a stable conjugate of a toxin or drug and an antibody or antibody fragment.

5 Another object of the present invention is to provide a medicaments for use in a method of treating patients having human cancers, lymphomas and leukemias.

Another object of the present invention is to provide a medicament for use in a method of treating patients with microbial and parasitic infections.

10 Another object of the present invention is to provide a medicaments for use in a method of treating patients with viral infections by destroying cells that are infected with the virus.

Upon further study of the specification and appended 15 claims, further objects and advantages of this invention will become apparent to those skilled in the art.

SUMMARY OF THE INVENTION

In one embodiment, the invention provides a toxin or drug conjugated to a protein which prior to conjugation has 20 at least one mercapto group which becomes a site for conjugation. The conjugate comprises a drug or modified toxin which is a native toxin devoid of a functional receptor-binding domain and a protein which reacts with a substance associated with a targeted cell or organism. The substance 25 internalizes the conjugate into the cell cytoplasm and the drug or toxin kills the cell.

In another embodiment, the invention provides a toxin or drug conjugated to an antibody or antibody fragment which prior to conjugation has at least one mercapto group which 30 becomes a site for conjugation. The conjugate comprises a drug or a modified toxin which is a native toxin devoid of a functional receptor-binding domain and an antibody or antibody fragment reactive with a tumor-associated antigen present on a cancer cell, e.g., B-cell lymphomas, wherein the 35 antigen internalizes the conjugate into the cancer cell.

In another embodiment, the invention provides a toxin or drug conjugated to an antibody or antibody fragment which,

prior to conjugation to the toxin or drug, has been treated to cleave disulfide bonds between the heavy chains to produce free sulfhydryl (mercapto) groups capable of being sites for conjugation. The conjugate comprises a drug or modified toxin 5 which is a native toxin devoid of a functional receptor-binding domain and an antibody or antibody fragment which reacts with a substance associated with a targeted cell or pathogen. The substance internalizes the conjugate into the cell or pathogen's cytoplasm.

10 In another embodiment, the invention provides a medicaments for use in a method of treating patients having human lymphomas and leukemias. The patient is administered a cytotoxic amount of a composition comprising an antibody or antibody fragment conjugate in a pharmaceutically acceptable 15 carrier. The conjugate comprises a modified toxin which is a native toxin deleted of a functional receptor-binding domain and an antibody or antibody fragment reactive with a tumor-associated antigen present on lymphomas. The antigen internalizes the conjugate into the malignant cell.

20 In another embodiment the invention provides a medicament for use in a method of cancer therapy. The method comprises parenterally injecting into a human subject having a cancer which produces or is associated with an antigen, a cytotoxic amount of an Fab' antibody fragment which is 25 specific to the antigen and which is conjugated with a modified toxin which is a native toxin lacking a functional receptor-binding region. The antigen internalizes the conjugate into the cancer cell.

30 In another embodiment, the invention provides a sterile injectable composition. The composition comprises a conjugate of a toxin or drug and an antibody or antibody fragment and a pharmaceutically acceptable injection vehicle. The conjugate comprises a drug or modified toxin which is a native toxin deleted of its functional receptor domain and an 35 antibody or antibody fragment reactive with an antigen present on a cancer cell or pathogen. The antigen internalizes the conjugate into the cell or pathogen.

In another embodiment, the invention provides a sterile injectable composition. The composition comprises a conjugate of a toxin and protein in a pharmaceutically acceptable injection vehicle. The conjugate comprises a drug or modified 5 toxin which is a native toxin devoid of a functional receptor-binding domain and a protein which reacts with a substance associated with a targeted cell or pathogen and which prior to conjugation has at least one mercapto group which becomes a site for conjugation. The substance 10 internalizes the conjugate into the cell cytoplasm.

In another embodiment, the invention provides a method for preparing a conjugate comprising a drug or a toxin devoid of a functional receptor-binding domain and a protein from a protein precursor having at least one disulfide linkage. The 15 method comprises (a) reacting a protein precursor with a disulfide reducing agent to form a dimercaptoprotein, and (b) contacting the toxin or drug with the dimercaptoprotein to form the conjugate.

In another embodiment, the invention provides a method 20 for producing a conjugate comprising a Fab' antibody fragment and a drug or a toxin devoid of a functional receptor-binding domain. The method comprises the steps of:

- (a) partially reducing an intact antibody with a reducing agent for cleaving disulfide groups, in an 25 amount sufficient to generate a plurality of proximal free sulfhydryl groups but insufficient to render immunologically inactive the antibody, and recovering the partially reduced antibody;
- (b) cleaving the partially reduced antibody to generate a reduced F(ab')₂ fragment; and
- (c) contacting a solution of the partially reduced F(ab')₂ fragment with a drug or a toxin devoid of a 30 functional binding domain.

In another embodiment, the invention provides a method 35 for producing a conjugate of a protein and toxin or drug. The method comprises the step of contacting, in solution, a mixture of (a) a protein containing at least one pendant

sulphydryl group and (b) drug or toxin devoid of a functional receptor-binding domain and recovering the resultant solution of conjugate.

DETAILED DESCRIPTION

5 Compositions and methods are provided related to toxins or drugs conjugated with a protein substances, as well as the use of the conjugates in cancer or infectious disease therapy. The cancer states include carcinomas, sarcomas, leukemias, lymphomas and myelomas. The infectious diseases 10 include those caused by invading microbes or parasites. As used herein, "microbe" denotes virus, bacteria, rickettsia, mycoplasma, protozoa, fungi and like microorganisms, "parasite" denotes infectious, generally microscopic or very small multicellular invertebrates, or ova or juvenile forms 15 thereof, which are susceptible to antibody-induced clearance or lytic or phagocytic destruction, e.g., malarial parasites, spirochetes and the like, including helminths, while "infectious agent" or "pathogen" denotes both microbes and parasites.

20 A method according to the invention thus broadly comprises the step of contacting a solution of a protein containing a plurality of spatially adjacent free sulphydryl (mercapto) groups with a solution of a toxin or drug, whereby a solution of a toxin or drug conjugated to protein is 25 obtained. Preferred embodiments of the method include applying the method of the invention to produce toxin- or drug-conjugated antibodies or antibody fragments useful for therapy.

30 A method according to the invention may be used to bind toxin or drug to other proteins with the requisite free sulphydryl (mercapto) groups. Proteins which contain one or more proximal free sulphydryl groups can be labeled directly. Those which contain disulfide groups, normally linked through a cysteine residue, can be treated with a reducing agent to 35 generate the free sulphydryl groups. This may result in fragmentation of the protein if the disulfide bond links polypeptide chains which are not continuous, or it may merely

result in chain separation, possibly involving a change in conformation of the protein if the disulfide bond joins remote segments of a single polypeptide chain. Genetic engineering may be used to produce proteins having free 5 sulfhydryl (mercapto) groups.

The protein substance may be a protein, peptide, polypeptide, glycoprotein, lipoprotein, or the like, e.g. hormones, lymphokines, growth factors, albumin, cytokines, enzymes, immune modulators, receptor proteins, antibodies and 10 antibody fragments.

The protein substance will be characterized by either having at least one free mercapto group or at least one accessible disulfide group which upon reduction will provide mercapto groups available as sites for conjugation.

15 The preferred protein substances are those reacting with a surface substance of a targeted cell, particularly a surface antigen wherein the conjugate becomes bound to the surface and then is endocytosed. Among surface antigens are surface membrane receptors, immunoglobulin, antibodies, 20 enzymes, naturally occurring receptors, lectins, and the like. Preferred are membrane receptors and intracellular antigens or receptors.

The protein substance of particular interest in the present invention are antibodies and antibody fragments. By 25 "antibodies and antibody fragments" is meant generally immunoglobulins or fragments thereof that specifically bind to antigens to form immune complexes.

The antibody may be whole immunoglobulin of any class, e.g., IgG, IgM, IgA, IgD, IgE, chimeric or hybrid antibodies 30 with dual or multiple antigen or epitope specificities. It can be a polyclonal antibody, preferably an affinity-purified antibody from a human or an appropriate animal, e.g., a primate, goat, rabbit, mouse or the like. Monoclonal antibodies are also suitable for use in the present 35 invention, and are preferred because of their high specificities. They are readily prepared by what are now considered conventional procedures of immunization of mammals

with immunogenic antigen preparation, fusion of immune lymph or spleen cells with an immortal myeloma cell line, and isolation of specific hybridoma clones. More unconventional methods of preparing monoclonal antibodies are not excluded, 5 such as interspecies fusions and genetic engineering manipulations of hypervariable regions, since it is primarily the antigen specificity of the antibodies that affects their utility in the present invention. It will be appreciated that newer techniques for production of monoclonals can also 10 be used, e.g., human monoclonals, interspecies monoclonals, chimeric (e.g., human/mouse) monoclonals, genetically engineered antibodies and the like.

Antibody fragments useful in the present invention include $F(ab')_2$, $F(ab)_2$, Fab' , Fab , Fv and the like including 15 hybrid fragments. Preferred fragments are Fab' , $F(ab')_2$, Fab , and $F(ab)_2$. Also useful are any subfragments retaining the hypervariable, antigen-binding region of an immunoglobulin and having a size similar to or smaller than a Fab' fragment. This will include genetically engineered and/or recombinant 20 proteins, whether, single-chain or multiple-chain, which incorporate an antigen binding site and otherwise function in vivo as targeting vehicles in substantially the same way as natural immunoglobulin fragments. Such single-chain binding molecules are disclosed in U.S. Patent 4,946,778, which is 25 hereby incorporated by reference. Fab' antibody fragments may be conveniently made by reductive cleavage of $F(ab')_2$ fragments, which themselves may be made by pepsin digestion of intact immunoglobulin. Fab antibody fragments may be made by papain digestion of intact immunoglobulin, under reducing 30 conditions, or by cleavage of $F(ab)_2$ fragments which result from careful papain digestion of whole immunoglobulin. The fragments may also be produced by genetic engineering.

It should be noted that mixtures of antibodies and immunoglobulin classes can be used, as can hybrid antibodies. 35 The hybrids can have two different antigen specificities. Hybrid antibody fragments with dual specificities can be prepared analogously to the anti-tumor marker hybrids

disclosed in U.S. Pat. No. 4,361,544. Other techniques for preparing hybrid antibodies are disclosed in, e.g., U.S. Pat. No. 4,474,893 and 4,479,895, and in Milstein et al., *Immunol. Today*, 5,299(1984).

5 Antibodies against tumor antigens and against pathogens are known. For example, antibodies and antibody fragments which specifically bind markers produced by or associated with tumors or infectious lesions, including viral, bacterial, fungal and parasitic infections, and antigens and 10 products associated with such microorganisms have been disclosed, *inter alia*, in Hansen et al., U.S. Patent 3,927,193 and Goldenberg U.S. Patents 4,331,647, 4,348,376, 4,361,544, 4,468,457, 4,444,744, 4,818,709 and 4,624,846. In particular, antibodies against an antigen, e.g., a 15 gastrointestinal, lung, breast, prostate, ovarian, testicular, brain or lymphatic tumor, a sarcoma or a melanoma, are advantageously used.

A wide variety of monoclonal antibodies against infectious disease agents have been developed, and are 20 summarized in a review by Polin, in *Eur. J. Clin. Microbiol.*, 3(5):387-398, 1984, showing ready availability. These include monoclonal antibodies (MAbs) against pathogens and their antigens such as the following:

Anti-bacterial Mabs

25 *Streptococcus agalactiae*
 Legionella pneumophilia
 Streptococcus pyogenes
 Escherichia coli
 Neisseria gonorrhosa
30 *Neisseria meningitidis*
 Pneumococcus
 Hemophilis influenzae B
 Treponema pallidum
 Lyme disease spirochetes
35 *Pseudomonas aeruginosa*
 Mycobacterium leprae
 Brucella abortus

Mycobacterium tuberculosis
Tetanus toxin
Anti-viral MAbs
HIV-1, -2, -3
5 Hepatitis A, B, C, D
Rabies virus
Influenza virus
Cytomegalovirus
Herpes simplex I and II
10 Human serum parvo-like virus
Respiratory syncytial virus
Varicella-Zoster virus
Hepatitis B virus
Measles virus
15 Adenovirus
Human T-cell leukemia viruses
Epstein-Barr virus
Murine leukemia virus*
Mumps virus
20 Vesicular stomatitis virus
Sindbis virus
Lymphocytic choriomeningitis virus
Wart virus
Blue tongue virus
25 Sendai virus
Feline leukemia virus*
Reo virus
Polio virus
Simian virus 40*
30 Mouse mammary tumor virus*
Dengue virus
Rubella virus
*=animal virus
Anti-protozoan MAbs
35 Plasmodium falciparum
Plasmodium vivax
Toxoplasma gondii

- Trypanosoma rangeli
- Trypanosoma cruzi
- Trypanosoma rhodesiensei
- Trypanosoma brucei
- 5 Schistosoma mansoni
- Schistosoma japonicum
- Babesia bovis
- Elmeria tenella
- Onchocerca volvulus
- 10 Leishmania tropica
- Trichinella spiralis
- theileria parva
- Taenia hydatigena
- Taenia ovis
- 15 Taenia saginata
- Echinococcus granulosus
- Mesocestoides corti
- Antimycoplasmal MAbs
- Mycoplasma arthritidis
- 20 M. hyorhinis
- M. orale
- M. arginini
- Acholeplasma laidlawii
- M. salivarium
- 25 M. pneumoniae

Additional examples of MAbs generated against infectious organisms that have been described in the literature are noted below.

- 30 MAbs against the gp120 glycoprotein antigen of human immunodeficiency virus 1 (HIV-1) are known, and certain of such antibodies can have an immunoprotective role in humans. See, e.g., Rossi et al., Proc. Natl. Acad. Sci. USA, 86:8055-8058, 1990. Other MAbs against viral antigens and viral induced antigens are also known. This shows that proper selection of the epitope can distinguish between a therapeutic and non-therapeutic target.

MAbs against malaria parasites can be directed against

the sporozoite, merozoite, schizont and gametocyte stages. Monoclonal antibodies have been generated against sporozoites (circumsporozoite antigen), and have been shown to neutralize sporozoites in vitro and in rodents (N. Yoshida et al., 5 Science 207:71-73, 1980).

Several groups have developed MAbs to *T. gondii*, the protozoan parasite involved in toxoplasmosis (Kasper et al., J. Immunol. 129:1694-1699, 1982; Id., 130:2407-2412, 1983).

MAbs have been developed against schistosomular surface 10 antigens and have been found to act against schistosomulae in vivo or in vitro (Simpson et al., Parasitology, 83:163-177, 1981; Smith et al., Parasitology, 84:83-91, 1982; Gryzch et al., J. Immunol., 129:2739-2743, 1982; Zodda et al., J. Immunol. 129:2326-2328, 1982; Dissous et al., J. Immunol., 15 129:2232-2234, 1982).

Trypanosoma cruzi is the causative agent of Chagas' disease, and is transmitted by blood-sucking reduviid insects. A MAb has been generated that specifically inhibits the differentiation of one form of the parasite to another 20 (epimastigote to trypomastigote stage) in vitro, and which reacts with a cell-surface glycoprotein; however, this antigen is absent from the mammalian (bloodstream) forms of the parasite (Sher et al., Nature, 300:639-640, 1982).

Suitable MAbs have been developed against most of the 25 microorganisms (bacteria, viruses, protozoa, parasites) responsible for the majority of infections in humans, and many have been used previously for in vitro diagnostic purposes. These antibodies, and newer MAbs that can be generated by conventional methods, are appropriate for use in 30 the present invention.

A preferred protein is an antibody or antibody fragment reactive with a tumor associated antigen present on carcinoma or sarcoma cells or lymphomas. One such antibody is disclosed, e.g., in Goldenberg et al., Journal of Clinical 35 Oncology, Vol 9, No. 4, pp. 548-564, 1991 and Pawlak et al., Cancer Research, Vol 49, pp. 4568-4577, 1989, as LL-2 and EPB-2, respectively, but which are the same antibody. These

references are hereby incorporated by reference. Another possibly useful antibody is LYM-1, presently being developed by Technicclone International Corp. for treatment of B-cell lymphoma.

5 It has now been found that a protein, in particular, an antibody or antibody fragment, having at least one free sulfhydryl (mercapto) group, can selectively conjugate toxins or drugs under mild conditions, to form tight bonds to the sulfhydryl group that are quite stable in blood and other
10 bodily fluids and tissues.

Antibodies and some antibody fragments contain one or more disulfide bonds which link the heavy chains, as well as disulfide bonds which join light and heavy chains together. The latter disulfide bonds are normally less accessible to
15 disulfide reducing agents and the bonds linking heavy chains can normally be selectively cleaved. The resultant fragments retain their immunospecificity and ability to bind to antigen. It will be understood that reduction of disulfide bonds linking the heavy chains of an immunoglobulin must be
20 effected with care, since the normally less reactive disulfide bonds linking light and heavy chains will eventually be reduced if reducing conditions are too drastic or the reducing agent is left in contact with the fragments for too long a time.

25 The reduction of the disulfide bond is advantageously effected with thiol reducing agents, e.g., cysteine, mercaptoethanol, dithioerythritol (DTE), dithiothreitol (DTT), glutathione and the like.

30 The reduction of the disulfide bonds of the disulfide protein, depending on conditions of the reaction, will either (a) only reduce some of the disulfide bonds present thus producing a mercaptoprotein from the disulfideprotein or (b) completely reduce all the disulfide bonds linking the heavy chains and thereby cleave the disulfideprotein to produce
35 fragments containing free mercapto sites.

Reduction of protein containing at least one disulfide bond, for example, an antibody or $F(ab')_2$ fragment, with known

disulfide bond reducing agents, e.g., dithiothreitol, cysteine, mercaptoethanol and the like, gives after a short time, typically less than one hour, including purification, antibody having from 1-10 free sulfhydryl (mercapto) groups 5 by analysis.

Reduction of $F(ab')$, fragments is preferably effected at pH 5.5-7.5, preferably 6.0-7.0, more preferably 6.4-6.8, and most preferably at about pH 6.6, e.g., in citrate, acetate or phosphate buffer, preferably phosphate-buffered saline, and 10 advantageously under an inert gas atmosphere. It is well known that thiol reduction can result in chain separation of the light and heavy chains of the fragment if care is not taken, and the reaction must be carefully controlled to avoid loss of integrity of the fragment.

15 Cysteine is preferred for such disulfide reductions and other thiols with similar oxidation potentials to cysteine will also be advantageously used. The ratio of disulfide reducing agent to protein is a function of interchain disulfide bond stabilities and must be optimized for each 20 individual case. Cleavage of $F(ab')$, antibody fragments is advantageously effected with 10-30mM cysteine, preferable about 20mM, and a protein concentration of about 10 mg/ml.

Reduction of a $F(ab')$, fragment with known disulfide bond 25 reducing agents gives, after a short time, typically less than one hour, including purification, Fab' typically having 1-3 free sulfhydryl groups by analysis.

The Fab -SH or Fab' -SH fragments are advantageously then passed through a short sizing gel column which will trap low molecular weight species, including excess reducing agent. 30 Suitable such sizing gel columns include, e.g., dextrans such as Sephadex G-25, G-50 (Pharmacia), Fractogel TSK HW55 (EM Science), polyacrylamides such as P-4, P-6 (BioRad), and the like. Cleavage can be monitored by, e.g., size exclusion HPLC, to adjust conditions so that Fab or Fab' fragments are 35 produced to an optimum extent, while minimizing light-heavy chain cleavage, which is generally less susceptible to disulfide cleavage.

The eluate from the sizing gel column is then stabilized in about 0.03 - 0.07, preferably about 0.05 M acetate buffer, pH about 4.5, made in about 0.1 - 0.3, preferably about 0.15 M saline, and preferably purged with an inert gas, e.g., 5 argon. In general, it is advantageous to work with a concentration of antibody fragment of about 0.5 - 5 mg per ml, preferably about 1 - 3 mg/ml, of solution.

In general, it is advantageous to work with a concentration of antibody or antibody fragment of about 0.01 10 - 10 mg per ml, preferably about 0.1 - 5 mg/ml, of solution, generally in saline, preferably buffered to a mildly acidic pH of about 4.0-4.5.

There are other methods known to those skilled in the art for reducing disulfide groups which are alleged to permit 15 radiolabeling with isotopes, such as technetium and rhenium. Such methods are disclosed in WO 88/07832, published October 6, 1988, U.S. Patent 4,877,868 to Reno et al. and U.S. Patent 5,078,985 to Rhodes, all incorporated herein by reference. While these disclosure are limited to radiolabeling, 20 modifications of the disclosed methods might be useful in the present invention to produce a protein with at least one mercapto group.

Once reduced, the protein containing a mercapto group is quite stable if stored under rigorously oxygen-free 25 conditions. Stability is also increased with storage at lower pH, particularly below pH 6. A more preferred method of stabilization is to lyophilize the solution of protein containing a mercapto group.

Drugs that interfere with intracellular protein 30 synthesis are known to those skilled in the art and include puromycin, cycloheximide, and ribonuclease.

Toxins are preferred for use in the methods and compositions of the present invention. Toxins useful as therapeutics are known to those skilled in the art and 35 include plant and bacterial toxins, such as, abrin, alpha toxin, diphtheria toxin, exotoxin, gelonin, pokeweed antiviral protein, ricin, and saporin.

Toxins in their native form require a minimum of three different biochemical functions to kill cells: a cell binding function, a cytotoxic function, and a function to translocate the toxic activity into the cells.

5 The modified toxins used in the present invention differ from native toxins in that the domain providing the cell binding function of the native toxin is nonfunctioning because the domain is missing partially or totally.

10 The drug or modified toxin is then treated by methods known to those skilled in the art to permit them to be conjugated to the protein containing at least one mercapto group.

15 Methods for treating toxins and, in particular, modified *Pseudomonas exotoxins*, are disclosed in Batkra et al., Proc. Natl. Acad. Sci. USA, Vol. 86, pp. 8545-8549, 1989; Seetharam et al., The Journal of Biol. Chem., Vol 266, no. 26, pp. 17376-17381, 1991; and Pastan et al., U.S. Patent 4,892,827, all incorporated herein by reference. A preferred modified *Pseudomonas exotoxin* comprises ADP ribosylating activate, an 20 ability to translocate across a cell membrane and devoid of a functional receptor binder region Ia of the native toxin. One such modified *Pseudomonas exotoxin* is devoid of amino acids 1-252 and 365-380 of native *Pseudomonas exotoxin* and contains a -KDEL mutation instead of -REDLK at the carboxyl 25 terminus.

When conjugating the foregoing quantity of antibody or antibody fragment, the amount of drug or toxin is generally about 0.25 to 5 times, preferably 1-3 times, the amount of antibody or antibody fragment, and the time of reaction is 30 about 10 to 120 minutes, preferably 30-90 minutes.

These conditions routinely result in substantially quantitative conjugation of the toxin into the protein in a form which is highly stable.

35 A physiological solution of the protein conjugate is advantageously metered into sterile vials, e.g., at a unit dosage of about 10.0 - 500 mg protein conjugate/vial, and the vials are either stoppered, sealed and stored at low

temperature, or lyophilized, stoppered, sealed and stored.

Variations and modifications of these kits will be readily apparent to the ordinary skilled artisan, as a function of the individual needs of the patient or treatment 5 regimen, as well as of variations in the form in which the radioisotopes may be provided or may become available.

Moreover, in a method of therapy of a patient suffering from a tumor or infectious lesion, wherein an antibody or antibody fragment which specifically binds to an antigen 10 produced by or associated with a tumor or an infectious lesion, and conjugated with a therapeutically effective toxin or drug, is parenterally injected into a human patient suffering from such tumor or infectious lesion, it will represent an improvement to use a toxin- or drug-conjugated 15 antibody or antibody fragment made according to the method of the present invention.

An important embodiment of the present invention involves the reduction of the immunogenicity of the toxin moiety of the conjugate with a carbohydrate polymer or polyol 20 groups. Examples include dextran, polysaccharides, polyethylene glycol (PEG), and the like.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The 25 following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. In the following examples, all temperatures are set forth uncorrected in degrees Celsius; unless otherwise indicated, 30 all parts and percentages are by weight.

EXAMPLES

Example 1 - A Masked Fab'/Toxin Conjugate

A. LL-2-IgG (disclosed above) is reduced with a low molecular weight mercaptan, converted to $F(ab')_2SH$ by 35 treatment with pepsin and purified by subtraction-chromatography on protein A and by diafiltration. All steps are performed under argon, using solutions that are purged

with argon.

B. A peptide linker containing lysine groups is synthesized. This peptide linker is reacted with highly purified 1'-carbonyldiimidazole-activated monofunctional polyethylene (PEG). The peptide linker-PEG-derivative is purified by gel-filtration (PEG-peptide) and ion-exchange chromatography.

5 C. The PEG-peptide is activated with succinimidyl 4-(N-maleimidomethyl-1-carboxylate (SMCC) and mixed with LL-2-F(ab')₂SH. The resultant LL-2-F(ab')₂-peptide-PEG is reduced with dithioerythritol, and the resultant PEG-peptide-LL-2-Fab'SH purified.

10 D. A modified Pseudomonas Exotoxin (mPE), lacking the Ia binding domain, is expressed in E. Coli, extracted from the periplasm, and purified by ion-exchange chromatography; mPE is activated by treatment with SMCC (AmPE).

15 E. The PEG-peptide-LL-2-Fab'SH is incubated with AmPE to obtain the therapeutic agent, LL-2-PEG-Fab'-SdPE, which is purified by gel-filtration chromatography.

20 Example 2 - Therapy with Masked Antibody Fragment and Toxin Conjugate

A patient having B-cell lymphoma refractory to treatment with chemotherapy is deemed not eligible for treatment by radioimmunotherapy because of extensive bone marrow infiltration by the cancer. The patient is treated by i.v. infusion with the conjugate of Example 1 and complete remission of the lymphoma is observed.

Example 3 - Anti-HIV Puromycin Conjugate

Balb/c mice are immunized with a synthetic peptide having the amino acid structure present in the amino-terminal end of the HIV (Human Immunodeficiency Virus) envelope protein, gp120. Hybridomas producing monoclonal antibodies reactive with gp120 are derived from spleen lymphocytes of the immunized mice using conventional methodology. The 30 monoclonal antibodies are evaluated for reactivity against different isolates of HIV. A MAb (mB1) which demonstrates 35 high affinity for all of the isolates is selected for use to

develop the anti-HIV puromycin conjugate. The mRNA of the hybridoma clone producing mB1 is isolated, and the sequence of CDRs of the heavy and light chain variable regions determined. Recombinant DNA techniques are then employed to 5 CDR-graft the hypervariable regions of the heavy and light chains onto cDNA of human IgG heavy and light chains cloned in M13 vectors. The genes encoding the variable regions are excised from the M13 vectors, and recloned into pSV2gpt (heavy chain) and pSV2neo (light chain plasmids containing 10 promoter and enhancer elements). The SP2/0 murine myeloma is transfected with the plasmids, and a hybridoma cell producing humanized antibody (hB1) is selected by cloning. The hB1-producing hybridoma is grown in a bioreactor, and hB1 is isolated from the culture media by ion-exchange 15 chromatography.

hB1-IgG is cleaved with pepsin, and the F(ab'), is purified by subtraction-chromatography on protein A and by diafiltration. hB1-IgG is converted to Fab' by reduction with cysteine and the Fab' purified by gel-filtration 20 chromatography; all steps are performed under argon, buffers are purged with argon, and the Fab'-SH is maintained under an argon atmosphere before being used to prepare the therapeutic conjugate.

Puromycin is derivatized to a linear polymer, containing 25 a lysine at one end and a translocation-peptide (GGGKDEL-COOH) at the other end. The polymer is activated by treatment with SMCC (APP).

hB1-Fab'-SH is incubated with APP to obtain the therapeutic conjugate, hB1-Fab'-S-APP.

30 A debilitated, febrile male patient infected with HIV, with a high titer of p24 HIV-antigen in his blood, is treated twice weekly with hB1-Fab'-S-AP given by i.v. injection. After two months of therapy, the patient's blood is negative 35 when tested for p24 HIV antigen, and his health is markedly improved.

The foregoing examples are merely illustrative and numerous variations and modifications can be effected by one

of ordinary skill in the art to adapt the method, kit and uses thereof according to the invention to various usages and conditions without departing from the scope and spirit of the invention.

5 The broad scope of the invention is defined by the appended claims, and by the myriad of equivalents thereof.

CLAIMS

1. A protein conjugated to a toxin or drug, wherein the conjugate comprises:
 - 5 a drug or modified toxin being a native toxin devoid of a functional receptor-binding domain, and
 - 10 a protein which reacts with a substance of a targeted cell or pathogenic microbe, wherein the targeted substance internalizes the conjugate into the cell or microbe's cytoplasm; and wherein the protein prior to conjugation has at least one mercapto group which becomes a site for conjugation.
2. The conjugate of claim 1, wherein the protein is a peptide, polypeptide, hormone, lymphokine, growth factor, albumin, cytokine, enzyme, immune modulator, receptor protein, antibody or antibody fragment.
3. The conjugate of claim 1, wherein the protein has at least one disulfide linkage which has been reduced to form a dimercaptoprotein prior to conjugation.
4. The conjugate of claim 3, wherein the dimercaptoprotein is an immunoglobulin, monoclonal antibody, or a specific binding fragment thereof.
5. The conjugate of claim 4, wherein the fragment is $F(ab)_2$ or $F(ab')_2$.
6. The conjugate of claim 1, wherein the protein is a Fv, single chain antibody, Fab or Fab'.
7. The conjugate of claim 1, wherein the protein is an antibody or antibody fragment reactive with a tumor-associated antigen present on lymphomas, carcinomas, sarcomas, leukemias or myelomas.
8. The conjugate of claim 7, wherein the fragment is $F(ab)_2$, $F(ab')_2$, Fab, or Fab'.
9. The conjugate of claim 1, wherein the toxin is abrin, alpha toxin, diphtheria toxin, exotoxin, gelonin, pokeweed antiviral protein, ricin, or saporin or the drug is puromycin, cycloheximide or ribonuclease.
- 35 10. The conjugate of claim 9, wherein the exotoxin is a modified *Pseudomonas* exotoxin.

11. The conjugate of claim 1, coupled with carbohydrate polymer or polyol groups to make the conjugate less immunogenic.
12. The conjugate of claim 11, wherein the carbohydrate polymer or polyol groups are dextran, polysaccharides, or polyethylene glycol (PEG).
13. The conjugate of claim 1, wherein the cell or pathogen's targeting substance is a membrane receptor.
14. The conjugate of claim 1, wherein the targeting substance is an intracellular antigen or receptor.
15. The conjugate of claim 1, wherein the targeting substance is a viral antigen or viral induced antigen.
16. An antibody or antibody fragment conjugated to a toxin or drug, wherein the conjugate comprises:
 - 15 a drug or modified toxin being a native toxin devoid of its functional receptor-binding domain; and
 - an antibody or antibody fragment reactive with a tumor-associated antigen present on a cancer cell, wherein the antigen internalizes the conjugate into the
 - 20 cancer cell; and wherein the antibody or antibody fragment prior to conjugation has at least one mercapto group which becomes a site for conjugation.
17. The conjugate of claim 16, wherein the fragment is a Fv, single chain antibody, Fab, Fab', F(ab), or F(ab')₂.
- 25 18. The conjugate of claim 16, wherein the fragment is F(ab)₂, F(ab')₂, Fab, or Fab'.
19. The conjugate of claim 16, wherein the toxin is abrin, alpha toxin, diphtheria toxin, exotoxin, gelonin, pokeweed antiviral protein, ricin, or saporin or the drug is
- 30 puromycin, cycloheximide or ribonuclease.
20. The conjugate of claim 19, wherein the exotoxin is a modified *Pseudomonas* exotoxin.
21. The conjugate of claim 16, coupled with carbohydrate polymer or polyol groups to make the conjugate less immunogenic.
- 35 22. The conjugate of claim 21, wherein the carbohydrate polymer or polyol groups are dextran, polysaccharides, or

polyethylene glycol (PEG).

23. An antibody or antibody fragment conjugated to a toxin or drug, wherein the conjugate comprises:

5 a drug or modified toxin being a native toxin devoid of its functional receptor-binding domain; and

10 an antibody or antibody fragment which reacts with a substance associated with a targeted cell or pathogen, wherein the substance internalizes the conjugate into the cell or pathogen's cytoplasm; and wherein the antibody or antibody fragment prior to conjugation to the toxin or drug, has been treated to cleave disulfide bonds between the heavy chains to produce free sulfhydryl groups capable of being sites for conjugation.

15 24. The conjugate of claim 23, wherein the fragment is a Fv, single chain antibody, Fab, Fab', F(ab)₂ or F(ab')₂.

25 25. The conjugate of claim 23, wherein the fragment is F(ab)₂, F(ab')₂, Fab, or Fab'.

20 26. The conjugate of claim 23, wherein the toxin is abrin, alpha toxin, diphtheria toxin, exotoxin, gelonin, pokeweed antiviral protein, ricin, or saporin or the drug is puromycin, cycloheximide or ribonuclease.

27. The conjugate of claim 26, wherein the exotoxin is a modified *Pseudomonas* exotoxin.

25 28. The conjugate of claim 23, coupled with carbohydrate polymer or polyol groups to make the conjugate less immunogenic.

29. The conjugate of claim 28, wherein the carbohydrate polymer or polyol groups are dextran, polysaccharides, or polyethylene glycol (PEG).

30 30. Use of

35 a composition comprising an antibody or antibody fragment conjugate in a pharmaceutically acceptable carrier, wherein the conjugate comprises a modified toxin being a native toxin deleted of its functional receptor-binding domain and an antibody or antibody fragment reactive with a tumor-associated antigen associated with lymphomas or leukemias,

in the preparation of a medicament for use in a method of treating patients having lymphomas and leukemias, wherein the patient is administered a cytotoxic amount of said medicament; and wherein said antigen internalizes the 5 conjugate into the malignant lymphoma or leukemia cells.

31. The use of claim 30, wherein the lymphoma is B-cell lymphoma or leukemia.

32. The use of claim 30, wherein the antibody fragment is Fv, single chain antibody, Fab, Fab', F(ab)₂, or 10 F(ab')₂.

33. The use of claim 30, wherein the toxin is abrin, alpha toxin, diphtheria toxin, exotoxin, gelonin, pokeweed antiviral protein, ricin, or saporin.

34. The use of claim 33, wherein the exotoxin is a 15 modified *Pseudomonas* exotoxin.

35. The use of claim 30, coupled with carbohydrate polymer or polyol groups to make the conjugate less immunogenic.

36. The use of claim 35, wherein the carbohydrate 20 polymer or polyol groups are dextran, polysaccharides, or polyethylene glycol (PEG).

37. The use of claim 30, wherein the antigen is a membrane receptor.

38. The use of claim 30, wherein the antigen is an 25 intracellular antigen or receptor.

39. Use of

a conjugate comprising a Fab' antibody fragment which is specific to an antigen produced by or associated with a tumor, said fragment being conjugated to a modified toxin 30 being a native toxin devoid of its functional receptor-binding region,

in the preparation of a medicament for use in a method of cancer therapy, which comprises parenterally injecting into a human subject having a cancer which produces or is 35 associated with said antigen, a cytotoxic amount of said medicament; and wherein said antigen internalizes the conjugate into the cancer cells.

40. The use of claim 39, wherein the toxin is abrin, alpha toxin, diphtheria toxin, exotoxin, gelonin, pokeweed antiviral protein, ricin, or saporin.

5 41. The use of claim 40, wherein the exotoxin is a modified *Pseudomonas* exotoxin.

42. The use of claim 39, coupled with carbohydrate polymer or polyol groups to make the conjugate less immunogenic.

10 43. The use of claim 42, wherein the carbohydrate polymer or polyol groups are dextran, polysaccharides, or polyethylene glycol (PEG).

44. The use of claim 39, wherein the antigen is a membrane receptor.

15 45. The use of claim 39, wherein the antigen is an intracellular antigen or receptor.

46. A sterile injectable composition, which comprises:

20 (a) an antibody conjugate or antibody fragment conjugate, wherein the conjugate comprises a drug or modified toxin being a native toxin deleted of its functional receptor-binding domain and an antibody or antibody fragment reactive with an antigen present on a cancer cell or pathogen, wherein the antigen internalizes the conjugate into the cell or pathogen; and

25 (b) a pharmaceutically acceptable injection vehicle.

47. The composition of claim 46, wherein the toxin is abrin, alpha toxin, diphtheria toxin, exotoxin, gelonin, pokeweed antiviral protein, ricin, or saporin.

48. A sterile injectable composition, which comprises:

30 (a) a protein conjugated to a toxin, wherein the conjugate comprises:

a modified toxin being a native toxin devoid of its functional receptor-binding domain; and

35 a protein which reacts with a substance of a targeted cell or pathogen, wherein the substance internalizes the conjugate into the cell cytoplasm, and wherein the protein prior to conjugation has at least one mercapto group which becomes a site for conjugation,

and

(b) a pharmaceutically acceptable injection vehicle.

49. The composition of claim 48, wherein the protein is a peptide, polypeptide, hormone, lymphokine, growth factor, 5 albumin, cytokine, enzyme, immune modulator, receptor protein, antibody or antibody fragment.

50. The composition of claim 48, wherein the protein is an immunoglobulin, monoclonal antibody, or a specific binding fragment thereof.

10 51. The composition of claim 50, wherein the protein is an antibody fragment.

52. The composition of claim 51, wherein the fragment is $F(ab)_2$, or $F(ab')_2$.

15 53. The composition of claim 51, wherein the fragment is a Fv, single chain antibody, Fab or Fab'.

54. The composition of claim 48, wherein protein is an antibody or antibody fragment reactive with a tumor-associated antigen present on lymphomas and leukemias.

20 55. The composition of claim 48, wherein protein is an antibody or antibody fragment reactive with a tumor-associated antigen present on cancer cells.

56. The composition of claim 48, wherein the protein is an antibody or antibody fragment reactive with an antigen associated with a pathogen.

25 57. The composition of claim 56, wherein the pathogen is a virus, protozoan, or bacterium.

58. The composition of claim 54, wherein the fragment is $F(ab)_2$, $F(ab')_2$, Fab, or Fab'.

30 59. The composition of claim 48, wherein the toxin is abrin, alpha toxin, diphtheria toxin, exotoxin, gelonin, pokeweed antiviral protein, ricin, or saporin or the drug is puromycin, cycloheximide or ribonuclease.

60. The composition of claim 59, wherein the exotoxin is a modified *Pseudomonas* exotoxin.

35 61. The composition of claim 48, coupled with carbohydrate polymer or polyol groups to make the conjugate less immunogenic.

62. The composition of claim 61, wherein the carbohydrate polymer or polyol groups are dextran, polysaccharides, or polyethylene glycol (PEG).

5 63. The composition of claim 48, wherein the antigen is a membrane receptor.

64. The composition of claim 48, wherein the antigen is an intracellular antigen or receptor.

65. The composition of claim 48, wherein the antigen is a viral antigen or viral induced antigen.

10 66. A method for preparing a conjugate comprising a drug or toxin devoid of a functional receptor-binding domain and a protein from a protein precursor having at least one disulfide linkage, the method comprising the steps of:

15 (a) reacting said protein precursor with a disulfide reducing agent to form a dimercaptoprotein; and

(b) contacting the toxin or drug with the dimercaptoprotein to form the conjugate.

20 67. The method of claim 66, wherein the protein precursor is a peptide, polypeptide, hormone, lymphokine, growth factor, albumin, cytokine, enzyme, immune modulator, receptor protein, antibody or antibody fragment.

68. The method of claim 66, wherein the protein precursor is an immunoglobulin, monoclonal antibody, polyclonal antibody, or specific binding fragment thereof.

25 69. The method of claim 66, wherein the antibody fragment is a $F(ab)_2$, $F(ab^*)_2$, Fab, or Fab^* .

70. The method of claim 66, wherein the dimercaptoprotein is stabilized prior to being contacted with the toxin.

30 71. The method of claim 69, wherein the dimercaptoprotein is stabilized by lyophilization.

72. A method for producing a conjugate comprising a Fab^* antibody fragment and a toxin or drug devoid of a functional receptor-binding domain comprising the steps of:

35 (a) partially reducing an intact antibody with a reducing agent for cleaving disulfide groups, in an amount sufficient to generate a plurality of proximal free

sulphydryl groups but insufficient to render immunologically inactive said antibody, and recovering partially reduced antibody;

5 (b) cleaving said partially reduced antibody to generate a reduced $F(ab') fragment; and$

(c) contacting a solution of said partially reduced $F(ab') fragment with a toxin or drug devoid of a functioning binding domain.$

73. A method for producing a conjugate of a protein and 10 toxin or drug, comprising the step of contacting, in solution, a mixture of (a) a protein containing at least one pendant sulphydryl group and (b) toxin or drug devoid of a functioning receptor binding domain, and recovering the resultant solution of conjugate.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/04136

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : A61K 37/00, 37/04; C07K 15/28, 15/14
US CL : 424/85.8; 530/387.1, 391.1, 391.7

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/85.8; 530/387.1, 391.1, 391.7

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DIALOG, APS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 5,061,641 (Shochat et al.), 29 October 1991, entire document, especially claims 1-35.	1-73
Y	US, A, 4,867,973 (Goers et al.) 19 September 1989, entire document, especially columns 10-13 and 19-21.	1-73
Y	Science, Volume 252, issued 21 June 1991, Thomas A. Waldmann; "Monoclonal antibodies in diagnosis and therapy", pages 1657-1662, especially pages 1660-1661.	1-73

Further documents are listed in the continuation of Box C. See patent family annex.

•	Special categories of cited documents:	
"A"	document defining the general state of the art which is not considered to be part of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier document published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

22 July 1993

Date of mailing of the international search report

02 AUG 1993

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

F. CHRISTOPHER EISENSCHENK

Facsimile No. NOT APPLICABLE

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*